Outpatient management of essential hypertension: a review based on the latest clinical guidelines.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: Helsinki : Finnish Medical Society Duodecim, 1989-

Hypertension*/drug therapy ; Cardiovascular Diseases*/prevention & control; Adult ; Humans ; United States ; Outpatients ; Essential Hypertension/drug therapy ; Comorbidity

Background: Essential hypertension, a prevalent cardiovascular condition, poses a significant health burden worldwide. Based on the latest American clinical guidelines, half of adults in the United States have hypertension. Of these, only about a half are treated and about a quarter are adequately controlled for hypertension. Given its impact on morbidity and mortality, ensuring effective management of high blood pressure is crucial to reduce associated risks and improve patient outcomes. Objective: This review aims to provide a comprehensive and up-to-date summary of the latest cardiology guidelines and evidence-based research on essential hypertension, with a focus on guiding outpatient clinical practice. Methods: The review evaluates both non-pharmacological approaches and pharmacological interventions to offer clinicians practical insights. Notably, it emphasizes the importance of individualized treatment plans tailored to patients' specific risk profiles and comorbidities. Results: By consolidating the latest advancements in hypertension management, this review provides clinicians with an up-to-date reference, offering a nuanced understanding of treatment goals and strategies. Conclusion: Through the incorporation of evidence-based recommendations, healthcare practitioners can optimize patient care, mitigate potential complications, and improve overall outcomes in essential hypertension.

Am J Clin Nutr. 2019 May 1;109(5):1273-1278. (PMID: 31051506)
Lancet. 2022 Dec 3;400(10367):1927-1937. (PMID: 36356632)
High Blood Press Cardiovasc Prev. 2020 Dec;27(6):547-560. (PMID: 33159664)
JAMA Netw Open. 2019 Mar 1;2(3):e190406. (PMID: 30848811)
N Engl J Med. 2023 Jul 20;389(3):228-238. (PMID: 37467498)
J Clin Hypertens (Greenwich). 2021 Mar;23(3):435-439. (PMID: 33484617)
Nat Rev Cardiol. 2023 Oct;20(10):647. (PMID: 37524808)
Prim Care. 2008 Sep;35(3):489-500, vi. (PMID: 18710666)
Lancet. 2021 Sep 11;398(10304):957-980. (PMID: 34450083)
Lancet. 2016 Mar 5;387(10022):957-967. (PMID: 26724178)
Br J Sports Med. 2019 Jul;53(14):859-869. (PMID: 30563873)
Hypertension. 2012 Aug;60(2):444-50. (PMID: 22753220)
Prev Med. 1987 Mar;16(2):235-51. (PMID: 3588564)
Curr Hypertens Rep. 2020 Jun 6;22(6):42. (PMID: 32506273)
N Engl J Med. 2010 Apr 29;362(17):1575-85. (PMID: 20228401)
Hypertension. 2015 May;65(5):1033-40. (PMID: 25733241)
JAMA. 1996 May 22-29;275(20):1557-62. (PMID: 8622246)
J Hypertens. 1999 May;17(5):597-601. (PMID: 10403602)
Toxics. 2021 Mar 09;9(3):. (PMID: 33803457)
Am J Ther. 2006 Jul-Aug;13(4):306-8. (PMID: 16858164)
Hypertension. 2004 Nov;44(5):595-601. (PMID: 15452024)
Obes Sci Pract. 2017 Mar;3(1):3-14. (PMID: 28392927)
J Am Heart Assoc. 2013 Feb 01;2(1):e004473. (PMID: 23525435)
Circulation. 2019 Aug 20;140(8):e382-e482. (PMID: 30586772)
Eur Heart J. 2016 Aug 1;37(29):2315-2381. (PMID: 27222591)
JAMA. 2018 Aug 14;320(6):566-579. (PMID: 30120478)
J Hypertens. 1994 Dec;12(12):1433-7. (PMID: 7706705)
Korean J Intern Med. 2019 Nov;34(6):1181-1187. (PMID: 31189302)
JACC Cardiovasc Interv. 2021 Dec 13;14(23):2614-2624. (PMID: 34743900)
Hypertension. 2018 Nov;72(5):e53-e90. (PMID: 30354828)
Curr Emerg Hosp Med Rep. 2020;8(3):103-109. (PMID: 32837803)
PLoS Med. 2009 Apr 28;6(4):e1000058. (PMID: 19399161)
Biomed Pharmacother. 2020 Jul;127:110196. (PMID: 32413670)
Hypertension. 2018 Sep;72(3):720-730. (PMID: 30012869)
Hypertension. 2005 Oct;46(4):637-42. (PMID: 16172420)
Nephrol Dial Transplant. 2018 Sep 1;33(9):1485-1493. (PMID: 29136223)
Kans J Med. 2022 Jun 20;15:220-221. (PMID: 35762001)
Lancet. 2010 Jul 10;376(9735):112-23. (PMID: 20561675)
Lancet. 2015 Nov 21;386(10008):2059-2068. (PMID: 26414968)
Hypertension. 2023 Apr;80(4):811-819. (PMID: 36762561)
Arch Intern Med. 2001 May 14;161(9):1183-92. (PMID: 11343441)
Cardiol Ther. 2019 Dec;8(2):157-166. (PMID: 31363987)
Lancet. 2011 Oct 22;378(9801):1485-92. (PMID: 21906798)
Kidney Int Rep. 2016 Jul;1(2):94-104. (PMID: 28164170)
Front Pharmacol. 2022 Sep 14;13:935823. (PMID: 36188627)
J Hypertens. 2013 Dec;31(12):2410-7. (PMID: 24029869)
Hypertension. 2008 Apr;51(4):960-9. (PMID: 18259046)
Can Med Assoc J. 1978 Nov 4;119(9):1034-9. (PMID: 369673)
J Hypertens. 2023 Jul 1;41(7):1108-1116. (PMID: 37016911)
Circulation. 2018 Oct 23;138(17):e426-e483. (PMID: 30354655)
Diabetol Metab Syndr. 2023 Jun 7;15(1):118. (PMID: 37280615)
Hypertension. 2021 Sep;78(3):591-603. (PMID: 34304580)
N Engl J Med. 2022 Jul 21;387(3):205-216. (PMID: 35658024)
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. (PMID: 27219496)
Lancet Reg Health Am. 2022 May;9:None. (PMID: 35711684)
Am J Hypertens. 1998 Apr;11(4 Pt 3):80S-87S. (PMID: 9607371)
Circ Res. 2017 Feb 3;120(3):439-448. (PMID: 28154096)
Nat Rev Nephrol. 2020 Apr;16(4):223-237. (PMID: 32024986)
Nat Med. 2022 Oct;28(10):2083-2091. (PMID: 36216945)
J Am Heart Assoc. 2016 Sep 28;5(10):. (PMID: 27680663)
Hypertension. 2020 Jun;75(6):1334-1357. (PMID: 32370572)
J Am Coll Cardiol. 2016 Jun 14;67(23):2802-2803. (PMID: 27282901)
Lancet. 2012 Dec 15;380(9859):2224-60. (PMID: 23245609)
J Am Soc Nephrol. 2018 Feb;29(2):383-388. (PMID: 29051347)
Circulation. 2007 Jul 31;116(5):572-84. (PMID: 17638929)
J Hypertens. 2015 Jul;33(7):1321-41. (PMID: 26039526)
N Engl J Med. 2022 Dec 29;387(26):2401-2410. (PMID: 36516076)
CMAJ. 2006 Jun 6;174(12):1737-42. (PMID: 16754904)
JAMA. 2003 May 21;289(19):2560-72. (PMID: 12748199)
Trends Cardiovasc Med. 2020 Feb;30(2):72-77. (PMID: 30926237)
Hypertension. 2003 Mar;41(3 Pt 2):625-33. (PMID: 12623970)
J Clin Hypertens (Greenwich). 2017 Apr;19(4):344-350. (PMID: 27378313)
Am J Hypertens. 1999 Dec;12(12 Pt 3):205S-213S. (PMID: 10619573)
Eur Heart J. 2023 Jun 20;44(23):2066-2077. (PMID: 36342266)
Am J Clin Nutr. 2004 Oct;80(4):1012-8. (PMID: 15447913)
Cardiovasc Drugs Ther. 1988 Jul;2(2):177-89. (PMID: 3154704)
BMJ. 2004 Jan 24;328(7433):204. (PMID: 14726370)
N Engl J Med. 2021 Sep 30;385(14):1268-1279. (PMID: 34491661)
Lancet. 2021 Sep 18;398(10305):1043-1052. (PMID: 34469767)
Hypertension. 2021 Nov;78(5):e38-e50. (PMID: 34538096)
N Engl J Med. 2001 Jan 4;344(1):3-10. (PMID: 11136953)
J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):433-445. (PMID: 29739234)
N Engl J Med. 2006 Jun 1;354(22):2368-74. (PMID: 16738273)
Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. (PMID: 11030016)
Am J Cardiol. 1986 Jan 24;57(2):14A-19A. (PMID: 3511652)
Eur J Clin Pharmacol. 1995;48(1):1-7. (PMID: 7621840)
Hypertension. 2016 Apr;67(4):733-9. (PMID: 26902492)
Clin Exp Pediatr. 2021 Mar;64(3):121-122. (PMID: 32972051)
Metab Syndr Relat Disord. 2011 Feb;9(1):1-12. (PMID: 20973675)
Am J Ther. 2022 May-Jun 01;29(3):e322-e333. (PMID: 30664018)
Hypertens Res. 2022 Nov;45(11):1802-1813. (PMID: 35701490)
N Engl J Med. 2008 Apr 10;358(15):1547-59. (PMID: 18378520)
Drugs. 2014 Mar;74(3):283-96. (PMID: 24554373)
BMJ. 2020 Feb 24;368:m315. (PMID: 32094151)
JAMA. 2019 Aug 6;322(5):409-420. (PMID: 31386134)
N Engl J Med. 2023 Apr 6;388(14):1342. (PMID: 37018506)
Am J Clin Nutr. 2016 Sep;104(3):576-86. (PMID: 27465384)
Circulation. 2011 Apr 19;123(15):1611-21. (PMID: 21464050)
Scand J Med Sci Sports. 2017 Mar;27(3):327-341. (PMID: 26891716)
Ren Fail. 2023 Dec;45(1):2163903. (PMID: 36637019)
Ann Intern Med. 1992 Aug 1;117(3):234-42. (PMID: 1616218)
World J Cardiol. 2014 Sep 26;6(9):878-89. (PMID: 25276290)
Hypertension. 2020 Nov;76(5):1368-1383. (PMID: 32921195)
N Engl J Med. 2021 Mar 18;384(11):989-1002. (PMID: 33567185)
Ann Pharmacother. 2018 Nov;52(11):1143-1151. (PMID: 29808707)
N Engl J Med. 2023 Feb 2;388(5):395-405. (PMID: 36342143)
J Hypertens. 2021 Jul 1;39(7):1293-1302. (PMID: 33710173)
J Hypertens. 2018 Oct;36(10):1953-2041. (PMID: 30234752)
Drug Saf. 1996 Jul;15(1):72-8. (PMID: 8862965)
Sports Med. 2018 Sep;48(9):2127-2142. (PMID: 29949110)
Lancet. 2018 Mar 10;391(10124):949-959. (PMID: 29499873)
BMJ. 1994 Jan 1;308(6920):18-21. (PMID: 8298346)
N Engl J Med. 2021 Dec 30;385(27):2507-2519. (PMID: 34739197)
Cochrane Database Syst Rev. 2017 Jan 20;1:CD002003. (PMID: 28107561)
Diabetes Care. 2013 Aug;36 Suppl 2:S312-24. (PMID: 23882065)
Arch Intern Med. 1984 Dec;144(12):2371-2. (PMID: 6391404)
Can J Cardiol. 2020 May;36(5):596-624. (PMID: 32389335)
Hypertension. 2021 Feb;77(2):692-705. (PMID: 33390044)
N Engl J Med. 2015 Nov 26;373(22):2103-16. (PMID: 26551272)

Keywords: blood pressure; essential hypertension; guidelines; hypertension; pharmacotherapy

Date Created: 20240411 Date Completed: 20240415 Latest Revision: 20240425

20240425

PMC11011233

10.1080/07853890.2024.2338242

38604225